Calmangafodipir, originated from mangafodipir, simulates the mitochondrial enzyme manganese superoxide dismutase (MnSOD), thereby reducing ROS and protecting against OIPN without apparent influence on tumour outcomes (Karlsson et al., 2015; Glimelius et al., 2018; Canta et al., 2020). The gene discussed is SOD2; the disease is neoplasm.